← ANALYST RATINGS · TIPRANKS
Celldex (CLDX): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy1 Hold0 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $66.17, the highest $100, the lowest $28.00. The average is +140.3% from the last price of $27.53.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $72.00 | Buy | +161.5% | Reiterated | 15.10.26on TipRanks 07:45 | +3.6%next day −3.7% | ↗ |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $28.00 → $27.00−3.6% | Hold | −1.9% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $28.00 → $27.00−3.6% | Hold | −1.9% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $31.00 → $28.00−9.7% | Hold | +1.7% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $30.00 → $27.00−10.0% | Hold | −1.9% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $31.00 → $28.00−9.7% | Hold | +1.7% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $28.00−9.7% | Hold | +1.7% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $61.00 → $72.00+18.0% | Buy | +161.5% | Reiterated | 13.10.26on TipRanks Oct 14 09:25 | −4.0%next day −0.4% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $38.00 → $28.00−26.3% | Hold | +1.7% | Reiterated | 05.10.26on TipRanks 07:40 | +2.3%next day −5.4% · 5 days −10.1% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $56.00 → $64.00+14.3% | Buy | +132.5% | Reiterated | 03.10.26on TipRanks 10:30 | +2.3%next day −5.4% · 5 days −10.1% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $64.00 | Buy | +132.5% | Reiterated | 02.10.26on TipRanks 08:55 | −2.4%next day +2.3% · 5 days −6.7% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $70.00 → $88.00+25.7% | Buy | +219.7% | Reiterated | 23.09.26on TipRanks 09:40 | −6.4%next day +1.2% · 5 days +4.8% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $60.00 | Buy | +117.9% | Reiterated | 23.09.26on TipRanks 07:15 | −6.4%next day +1.2% · 5 days +4.8% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $57.00 | Buy | +107.0% | Assigned | 23.09.26on TipRanks 06:26 | −6.4%next day +1.2% · 5 days +4.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $100 | Buy | +263.2% | Reiterated | 22.09.26on TipRanks Sep 23 07:10 | −11.5%next day −6.4% · 5 days −4.4% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $58.00 → $68.00+17.2% | Buy | +147.0% | Assigned | 22.09.26on TipRanks Sep 23 06:14 | −11.5%next day −6.4% · 5 days −4.4% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $53.00 | Buy | +92.5% | Reiterated | 22.09.26on TipRanks Sep 23 05:05 | −11.5%next day −6.4% · 5 days −4.4% | ↗ |
| Unknown Analyst | Jefferies | $68.00 | Buy | +147.0% | Reiterated | 07.08.26on TipRanks 16:25 | +3.0%next day +3.5% · 5 days −2.4% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $45.00 | Buy | +63.5% | Reiterated | 16.06.26on TipRanks Jun 18 07:45 | +1.2%next day +3.1% · 5 days +6.5% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $51.00 → $44.00−13.7% | Buy | +59.8% | Reiterated | 14.06.26on TipRanks Jun 15 07:50 | +1.0%next day +1.2% · 5 days +5.2% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | — | Buy | — | Reiterated | 07.05.26on TipRanks 21:15 | +1.1%next day −5.2% · 5 days −8.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Celldex
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $65.25 at a price of $32.41 (+101.3%); now: $66.17 at $27.53 (+140.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 14 | 14 | 20 | 16 |
| Buy | 6 | 9 | 11 | 14 | 11 | 8 |
| Hold | 2 | 1 | 2 | 2 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.02 (from $-1.07 to $-0.94). Last quarter: $-0.94.
Sales
Next quarter’s sales estimate — $1M (from $0M to $3M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Celldex
- CEO: Anthony S. Marucci
- Employees: 198
- Perryville III Building, Hampton, NJ, 08827, US
- www.celldex.com
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Data from the stock’s TipRanks forecast page, read 10 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗